Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million ...

Moderna Inc. said it will reduce its global workforce by roughly 10% before year’s end, responding to sharply reduced demand ...

Just one day after CEO Stéphane Bancel’s sudden announcement of a 10% workforce reduction, Moderna has released Q2 2025 that that fell short of analyst expectations.

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

US mRNA specialist Moderna has today reported financial results and provided business updates for the second quarter of 2025, ...

Shares of Moderna fell sharply Friday after the company lowered the top end of its full-year revenue outlook because of a ...

Moderna Inc. shares declined as the company’s cost-cutting efforts failed to assuage investors who are worried about the ...

In a memo, CEO Stéphane Bancel said the job cuts are needed to align the struggling vaccine maker’s cost structure with the ...

US mRNA specialist Moderna has announced that the UK Court of Appeal has upheld the validity of its EP'949 patent.

Moderna is due to report its second-quarter financial results on Friday ahead of the market open, a day after announcing ...

Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult ...

The biotechnology company on Friday said the U.K. Court of Appeal upheld the validity of its EP'949 patent. It noted that the decision affirms the court's initial ruling from July 2024 that the patent ...